NGNE · Company research
Neurogene, Inc. Common Stock (NGNE): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Trading Systems Reacting to (NGNE) Volatility - Stock Traders Daily | Trading Systems Reacting to (NGNE) Volatility Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 16, 2026 | neutral | 0 | 0.6 |
| NGNE Oct 2026 40.000 call (NGNE261016C00040000) Interactive Stock Chart - Yahoo! Finance Canada | NGNE Oct 2026 40.000 call (NGNE261016C00040000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| NGNE Oct 2026 50.000 call (NGNE261016C00050000) Stock Price, News, Quote & History - Yahoo! Finance Canada | NGNE Oct 2026 50.000 call (NGNE261016C00050000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Neurogene (Nasdaq:NGNE) - Stock Analysis - Simply Wall Street | Neurogene (Nasdaq:NGNE) - Stock Analysis Simply Wall Street | View source ↗ | Simply Wall Street | Oct 15, 2026 | neutral | 0 | 0.6 |
| $NGNE stock is down 10% today. Here's what we see in our data. - Quiver Quantitative | $NGNE stock is down 10% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 13, 2026 | neutral | 0 | 0.6 |
| Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? | Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Neurogene Inc (NGNE-Q) Stock Price and News - The Globe and Mail | Neurogene Inc (NGNE-Q) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 10, 2026 | neutral | 0 | 0.6 |
| Neurogene stock a new Overweight at J.P. Morgan (NGNE:NASDAQ) - Seeking Alpha | Neurogene stock a new Overweight at J.P. Morgan (NGNE:NASDAQ) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 8, 2026 | neutral | 0 | 0.6 |
| Prudential reports a passive Neurogene (NGNE) stake spanning more than 2 million shares. - Stock Titan | Prudential reports a passive Neurogene (NGNE) stake spanning more than 2 million shares. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| A passive investor reports 2.23 million shares of Neurogene (NGNE). - Stock Titan | A passive investor reports 2.23 million shares of Neurogene (NGNE). Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Precision Trading with Neoleukin Therapeutics Inc. (NGNE) Risk Zones - Stock Traders Daily | Precision Trading with Neoleukin Therapeutics Inc. (NGNE) Risk Zones Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 6, 2026 | neutral | 0 | 0.6 |
| NGNE Dec 2027 17.500 call (NGNE271217C00017500) Interactive Stock Chart - Yahoo! Finance Canada | NGNE Dec 2027 17.500 call (NGNE271217C00017500) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 4, 2026 | neutral | 0 | 0.6 |
| NGNE Technical Analysis | Trend, Signals & Chart Patterns - ChartMill | NGNE Technical Analysis | Trend, Signals & Chart Patterns ChartMill | View source ↗ | ChartMill | Sep 28, 2026 | neutral | 0 | 0.6 |
| $NGNE stock is down 9% today. Here's what we see in our data. - Quiver Quantitative | $NGNE stock is down 9% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 25, 2026 | neutral | 0 | 0.6 |
| Neurogene Inc. (NGNE) Stock Price & News - Syfe | Neurogene Inc. (NGNE) Stock Price & News Syfe | View source ↗ | Syfe | Sep 25, 2026 | neutral | 0 | 0.6 |
| Several Neurogene Insiders Sell Shares Sending Potential Negative Signal - Simply Wall Street | Several Neurogene Insiders Sell Shares Sending Potential Negative Signal Simply Wall Street | View source ↗ | Simply Wall Street | Sep 19, 2026 | neutral | 0 | 0.6 |
| NGNE Forecast — Price Target — Prediction for 2027 - TradingView | NGNE Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target - Stocktwits | This $20 Biotech Stock Just Got An FDA Boost – And A $200 Price Target Stocktwits | View source ↗ | Stocktwits | Feb 27, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.